BCHTHIGH SIGNALREGULATORY10-K

BCHT has added extensive PFAS chemical definitions to their 10-K while removing all language related to financial statement restatements, coinciding with dramatic improvements in financial performance including 1292% cash increase and 72% reduction in net losses.

The addition of specific PFAS (per- and polyfluoroalkyl substances) chemical definitions suggests BCHT is now subject to new EPA drinking water regulations, indicating either a business pivot into water treatment or expanded regulatory compliance requirements. The removal of restatement language suggests the company has resolved previous accounting errors and moved past financial reporting issues that required extensive corrections in the prior period.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

BCHT shows remarkable financial improvement with cash surging from $1.5M to $20.9M and net losses improving 72% from -$10.8M to -$3.0M, while operating cash flow improved significantly from -$4.1M to -$700K. However, stockholders' equity turned negative from $1.2M to -$1.7M, indicating the company remains financially distressed despite the cash infusion. The combination of massive cash increase with negative equity suggests potential dilutive financing or debt conversion that has strengthened liquidity but at the cost of shareholder value.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+1292.1%
$1.5M$20.9M

Cash position surged 1292.1% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
-243.9%
$1.2M-$1.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-96.4%
$809K$29K

Capex reduced 96.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
-94.9%
$267K$14K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
+82.9%
-$4.1M-$700K

Operating cash flow surged 82.9% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+72%
-$10.8M-$3.0M

Net income grew 72% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+57.7%
-$7.2M-$3.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

SG&A Expense
P&L
-39.7%
$14.2M$8.6M

SG&A reduced 39.7% — improved cost efficiency or headcount reduction improving operating margins.

Inventory
Balance Sheet
-27.9%
$622K$448K

Inventory reduced 27.9% — lean inventory management or demand outpacing supply.

Current Liabilities
Balance Sheet
+22%
$8.8M$10.7M

Current liabilities rose 22% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
Hazard Index MCL means a regulatory limit used by the EPA to address safe drinking water when mixtures of certain PFAS are present.
HFPO-DA means hexafluoropropylene oxide dimer acid, which is a specific type of chemical within the PFAS group.
PFBS means perfluorobutanesulfonic acid, which is a specific type of chemical within the PFAS group.
PFHxS means perfluorohexane sulfonic acid, which is a specific type of chemical within the PFAS group.
PFNA means perfluorononanoic acid, which is a specific type of chemical within the PFAS group.
+7 more — sign up free →
REMOVED
(the Company, us, our ) includes a restatement of the following financial statements (collectively, the Restated Financial Statements ) as appearing in the Company s Annual Reports on Form 10-K for the fiscal years ended December 31, 2023 and 2022 and its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, June 30 and September 30 in each of 2024 and 2023 (collectively, the Prior Periodic Reports ): 1.
Our consolidated balance sheets as of December 31, 2023 and as of December 31, 2022, our consolidated statements of operations and consolidated statements of cash flows for the years ended December 31, 2023 and December 31, 2022 and the accumulated deficit in our consolidated statements of stockholders equity as of December 31, 2023 and January 1, 2023 (see Note 2, Restatement of Previously Issued Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K); and 2.
Restatement Overview As disclosed by the Company in Item 4.02 of the Form 8-K filed on March 31, 2025, in connection with the preparation of this Annual Report, management identified an error in the previously reported financial statements related to the under recognition of revenue during the year ended December 31, 2022 and, therefore, the Prior Periodic Reports would need to be restated.
See, Note 2, Restatement of Previously Issued Financial Statements and Note 16, Restatement of Quarterly Financial Information (Unaudited) in the notes to the consolidated financial statements included in this Annual Report on Form 10-K.
The Items of this Annual Report on Form 10-K that restate information in the Prior Periodic Reports as a result of the Restated Financial Statements include: 1.
+7 more — sign up free →
MORE REGULATORY SIGNALS
OMERHIGHOMER achieved FDA approval for YARTEMLEA in December 2025, transforming from a c...
2026-03-31
UNCYHIGHThe FDA issued a Complete Response Letter (CRL) in June 2025 rejecting UNCY's dr...
2026-03-30
NVNOHIGHNVNO received a not-approvable letter from the FDA for its lead product VenoValv...
2026-03-26
ABEOHIGHABEO received FDA approval for ZEVASKYN, its first commercial product for treati...
2026-03-17
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →